. 2025 Mar 27;16:1541507. doi: 10.3389/fneur.2025.1541507

Table 3.

Comparison of treatment age groups based on CHOP-INTEND score.

CHOP-INTEND score	The age at the initiation of treatment					Total (n = 310)	p- value
CHOP-INTEND score	Cohort A (n = 46)	Cohort B (n = 147)	Cohort C (n = 49)	Cohort D (n = 35)	Cohort E (n = 33)	Total (n = 310)	p- value
Baseline	22.00 (15.00–29.25)^c	19.00 (12.00–28.00)^c	14.00 (7.00–22.00)^b	9.00 (5.00–14.00)^ab	6.00 (3.00–11.00)^a	16.00 (8.00–24.25)	<0.001
T6	39.50 (27.00–45.00)^c	33.50 (20.25–44.00)^c	21.00 (13.75–32.00)^b	14.00 (8.00–26.00)^ab	11.00 (7.50–14.00)^a	28.00 (15.00–41.75)	<0.001
T14	50.00 (36.75–58.00)^b	45.00 (32.75–56.00)^b	20.50 (11.00–42.25)^a	15.50 (7.50–31.50)^a	13.00 (9.00–17.00)^a	35.00 (15.00–53.00)	<0.001
T26	55.00 (41.50–62.00)^c	54.00 (31.50–60.00)^bc	20.50 (7.50–48.75)^ab	15.00 (5.00–23.00)^a	12.00 (8.00–17.50)^a	39.50 (12.75–58.00)	<0.001
T38	57.00 (47.50–64.00)^b	60.00 (31.50–63.00)^b	35.00 (13.50–58.75)^ab	22.00 (6.00–31.00)^ab	12.50 (8.25–18.50)^a	31.50 (12.75–60.00)	<0.001
T46	60.00 (40.00–60.00)	43.00 (39.00–43.00)	18.00 (17.00–18.00)	15.50 (9.00–15.50)	10.00 (5.00–19.50)	22.00 (12.00–60.00)	0.068
Post-treatment	43.50 (32.00–60.00)^c	39.00 (21.00–54.00)^c	20.00 (12.50–32.00)^b	15.00 (7.00–25.00)^ab	11.00 (6.50–16.00)^a	28.50 (14.00–45.00)	<0.001
4 points increase n (%)	43 (93.5)^a	119 (81.0)^a	35 (71.4)^ab	19 (54.3)^bc	11 (33.3)^c	227 (73.2)	<0.001
40 points increase n (%)	31 (67.4)^a	72 (49.0)^a	10 (20.4)^b	1 (2.9)^b	0 (0.0)^b	114 (36.8)	<0.001
64 points increase n (%)	10 (21.7)^a	15 (10.2)^ab	1 (2.0)^b	0 (0.0)^b	0 (0.0)^b	26 (8.4)	<0.001

SMA, Spinal Muscular Atrophy. Statistically significant values are in bold. Values are shown as median (1st-3rd quartiles). In post hoc comparisons the same superscripts indicate similarities among groups, while different superscripts indicate a statistically significant differences among groups.